risperidone has been researched along with Borderline Personality Disorder in 9 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Borderline Personality Disorder: A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 9.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| "Of the various Axis II disorders, borderline personality disorder (BPD) is among the more critical to treat." | 6.70 | Treatment of borderline personality disorder with risperidone. ( Bogetto, F; Cocuzza, E; Marchiaro, L; Rocca, P, 2002) |
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 5.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| "Of the various Axis II disorders, borderline personality disorder (BPD) is among the more critical to treat." | 2.70 | Treatment of borderline personality disorder with risperidone. ( Bogetto, F; Cocuzza, E; Marchiaro, L; Rocca, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Houston, JP | 1 |
| Kohler, J | 1 |
| Bishop, JR | 1 |
| Ellingrod, VL | 1 |
| Ostbye, KM | 1 |
| Zhao, F | 1 |
| Conley, RR | 1 |
| Poole Hoffmann, V | 1 |
| Fijal, BA | 1 |
| Carrasco, JL | 1 |
| Palomares, N | 1 |
| Marsá, MD | 1 |
| Grootens, KP | 1 |
| Verkes, RJ | 1 |
| Weiden, P | 1 |
| Marchesi, C | 1 |
| Tonna, M | 1 |
| Maggini, C | 1 |
| Friedel, RO | 1 |
| Jackson, WT | 1 |
| Huston, CS | 1 |
| May, RS | 1 |
| Kirby, NL | 1 |
| Stoves, A | 1 |
| Khouzam, HR | 1 |
| Donnelly, NJ | 1 |
| Szigethy, EM | 1 |
| Schulz, SC | 1 |
| Rocca, P | 1 |
| Marchiaro, L | 1 |
| Cocuzza, E | 1 |
| Bogetto, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo[NCT00088036] | Phase 3 | 450 participants | Interventional | 2004-02-29 | Completed | ||
| Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549] | Phase 4 | 500 participants | Interventional | 2004-10-31 | Completed | ||
| The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321] | Phase 3 | 600 participants | Interventional | 2002-04-30 | Completed | ||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo[NCT00091650] | Phase 3 | 300 participants | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for risperidone and Borderline Personality Disorder
| Article | Year |
|---|---|
Emerging evidence for the use of atypical antipsychotics in borderline personality disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Borderline Personality Disorder; Clinical Trials as Topic; Cl | 2005 |
3 trials available for risperidone and Borderline Personality Disorder
| Article | Year |
|---|---|
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Effectiveness and tolerability of long-acting intramuscular risperidone as adjuvant treatment in refractory borderline personality disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Borderline Personality Disorder; Delayed-Action Preparation | 2012 |
Treatment of borderline personality disorder with risperidone.
Topics: Adult; Aggression; Antipsychotic Agents; Borderline Personality Disorder; Dopamine Antagonists; Fema | 2002 |
5 other studies available for risperidone and Borderline Personality Disorder
| Article | Year |
|---|---|
Splitting and pill splitting.
Topics: Adult; Aged; Borderline Personality Disorder; Cost Savings; Defense Mechanisms; Drug Costs; Female; | 2007 |
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.
Topics: Adolescent; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Antipsychotic Agents; B | 2009 |
Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder-specific outcome measure: a pilot study.
Topics: Adult; Antipsychotic Agents; Borderline Personality Disorder; Dose-Response Relationship, Drug; Drug | 2008 |
Remission of self-mutilation in a patient with borderline personality during risperidone therapy.
Topics: Adult; Borderline Personality Disorder; Female; Humans; Impulsive Behavior; Risperidone; Self Mutila | 1997 |
Risperidone in comorbid borderline personality disorder and dysthymia.
Topics: Adult; Alcoholism; Antipsychotic Agents; Borderline Personality Disorder; Comorbidity; Dysthymic Dis | 1997 |